
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics Inc. has demonstrated a strong financial performance and growth potential, as evidenced by a 63.3% year-over-year increase in Q3 revenue, totaling $27.3 million, which exceeded previous estimates. The company has also updated its revenue forecasts, raising estimates for 2025 and 2026 to $97.5 million and $136 million, respectively, reflecting strong momentum from new patient starts, particularly through the pharmacy channel. Additionally, Beta Bionics is successfully expanding its market presence, with 70% of new patient starts coming from conversions from multiple daily injections, which is expected to drive robust, higher-margin sales growth in the coming years.
Bears say
Beta Bionics Inc faces significant risks that contribute to a negative outlook on its stock, including challenges in gaining meaningful market share for its iLet product amid competitive pressures and potential delays in clinical development timelines. The company's financial performance is under scrutiny due to an EBITDA loss of $12.2 million, substantially exceeding previous estimates, highlighting operational inefficiencies and a sluggish sales force ramp-up. Additionally, the implications of evolving Medicare reimbursement policies and the anticipated need for additional capital could exert downward pressure on revenue, profitability, and shareholder value, creating a complex financial landscape for the company.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares